Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses the challenges that biosimilar developers face in getting their products to market.
Transcript:
What are some of the biggest challenges in getting a biosimilar to market from a manufacturer’s perspective?
Well, I think it starts with the intellectual property (IP) situation in the United States, right? It's so different, and it's kind of a unique situation in the United States. You know, usually the [United States] leads innovation. In the case of biosimilars, we're about 10 to 12 years behind the rest of the world, largely because of the IP situation and what we call the "patent estates" that a number of the originator companies have been able to put up.
The second big sort of challenge and obstacle, I think, has been in the past more of a policy sort of challenge where biosimilars were to some extent disadvantaged, whether it was through CMS or the FDA, and other things. So, from a policy perspective, just in the last 6 months I never could have imagined that we would have seen some of the policy solutions that have been put forward by the government.
So we've resolved some of those to at least I would say get biosimilars to be equivalent to the originator. I think our hope now is, is there not a policy opportunity for us to now maybe enable biosimilars by giving them more of a favorable sort of policy pathway, and certainly that's the energy that we're feeling from [FDA Commissioner Scott Gottlieb, MD] and other officials in the government is to try to now really enable the biosimilar uptake.
And then the final one, I think, is really the system in the United States with what everyone's referring to today as the “rebate wall” certainly is a big hurdle for us in terms of "how do we overcome that?" And, again, I think Americans are looking for a lot more transparency. It's a very complicated system compared to other countries. But, you know, we're now at a stage where we have at Sandoz 86 countries where we've been successfully marketing biosimilars.
The time feels right to us that some of these challenges will start knocking down pretty quickly. I think the [United States] is definitely ready to free up the capacity to fund these innovations. I mean, you know, even in oncology when you think about what's happened from an innovation perspective in the last 5 years, if we don't create the room in the marketplace to take advantage of these savings now, then we're not going to be able to have access to these new innovations, and I think that's what really excites us the most at Sandoz in terms of the value that we can create for Americans in the US healthcare system.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.